Red cell alloimmunization in beta thalassemia patients

Status: 
Ready to upload
Record number: 
1650
Adverse Occurrence type: 
MPHO Type: 
Estimated frequency: 
A total of 14 out of 162 (8.6%) patients developed alloantibodies against red cell antigens. The most frequently occurring alloantibodies were anti-E (2.5%), anti-K (1.8%), anti-e (1.2%) and anti-D (0.6%). Five (3.1%) patients developed more than one red blood cell (RBC) alloantibody.
Alerting signals, symptoms, evidence of occurrence: 
In total 162 beta thalassemia patients were included in this study. Patients received red cell concentrates, which were matched for ABO and Rh(D) antigens. Clinical and laboratory data were collected and analysed to estimate the frequency of alloantibodies and the factors influencing immunisation in patients on regular blood transfusion. The most frequently occurring alloantibodies were anti-E (2.5%), anti-K (1.8%), anti-e (1.2%) and anti-D (0.6%). Five (3.1%) patients developed more than one red blood cell (RBC) alloantibody.
Demonstration of imputability or root cause: 
An extended red cell antigen panel was performed to detect antibodies.
Imputability grade: 
3 Definite/Certain/Proven
Groups audience: 
Suggest new keywords: 
Alloimmunisation, beta-thalassemia, red cell transfusion, Rh, Kell, red cell alloantibodies, anti-E, anti-K, anti-e, anti-D
Reference attachment: 
Suggest references: 
Zaidi, U., Borhany, M., Ansari, S., Parveen, S., Boota, S., Shamim, I., Zahid, D. and Shamsi, T. (2015). Red cell alloimmunisation in regularly transfused beta thalassemia patients in Pakistan. Transfus Med 25(20:106-110.
Note: 
OK ONCE THE REFERENCE IS INDEXED (EVI)
Expert comments for publication: 
The frequency of transfusion was increased in patients who developed alloantibodies. Typing patients and donors to match for Rh and Kell antigens would prevent more than 90% of RBC alloantibodies and reduce the frequency of transfusion in thalassemia patients.